Mounzer Agha, MD, University of Pittsburgh Medical Center, Pittsburgh.
Victoria Graham, Washington, DC.
Joshua Katz, MD, co-director, Elliot Lewis Center, Wellesley, MA.
Dorry Segev, MD, PhD, Johns Hopkins University School of Medicine, Baltimore.
Therapeutic Advances in Neurologic Disorders: “Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.”
Annals of the Rheumatic Diseases: “Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.”
JAMA Network: “Prevalence of Immunosuppression Among US Adults 2013.”
The Lancet: “Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in People Living with HIV-1.”
NEJM Journal Watch, June 14, 2021.
CDC: “Joint CDC and FDA Statement on Vaccine Boosters,” “COVID-19, People with Certain Medical Conditions.”
MedRxiv: “Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients,” “Serological response to COVID-19 vaccination in IBD patients receiving biologics.”
Annals of Internal Medicine: “Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.”
JAMA: “Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients,” “Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.”
View original article here Source